Chemomab Therapeutics Ltd (CMMB) Stock Analysis
Verdict: AVOID
Clinical binary risk outweighs recent technical momentum; the $7.5M cash bridge is insufficient for Phase 3 without massive dilution.
Investment score: 38/100
Analysis as of
Is Chemomab Therapeutics Ltd stock worth reviewing? AI model thesis
Chemomab is a pre-revenue microcap facing a liquidity crunch despite promising clinical targets. The model prioritizes the high probability of dilution over recent price strength.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 65/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 70/100 (weight 10%)
- Analyst Consensus: 60/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
Chemomab Therapeutics Ltd opportunities and risks
What speaks for CMMB
- First-in-Class Potential for CM-101
What speaks against CMMB
- Imminent Liquidity Crunch and Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CMMB | n/a | 0.0x | n/a | 0.0% | 0.0% | -94.5% |
| PLRZ | n/a | 0.0x | n/a | 0.0% | 0.0% | -31.3% |
| PLUR | n/a | 15.2x | n/a | 19.0% | -2424.7% | -132.5% |
| NRSN | n/a | 0.0x | n/a | 0.0% | 0.0% | -20.8% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -31.3% |
Frequently asked questions about Chemomab Therapeutics Ltd (CMMB)
Is CMMB stock a good investment?
The cached TradeMates AI model rates Chemomab Therapeutics Ltd as AVOID with an investment score of 38/100. Chemomab is a pre-revenue microcap facing a liquidity crunch despite promising clinical targets. The model prioritizes the high probability of dilution over recent price strength. This is algorithmic model output, not personal investment advice.
Is CMMB stock a buy?
The TradeMates model verdict for CMMB is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.